Debiopharm and ITM announced a licensing deal for a radiopharmaceutical treatment that’s being investigated in several cancers.
Debiopharm, which is based in Switzerland, is eligible …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.